Resources & Guides

No FDA label or guideline sets one lab schedule for everyone on a GLP-1. Here is what the Wegovy, Ozempic, Zepbound and Mounjaro labels and ADA 2026 actually say about kidney, pancreas, liver, blood sugar, thyroid and nutrition labs, what we suggest on top, and which symptoms need a doctor today.

Complete tirzepatide dosage chart showing Mounjaro and Zepbound titration protocols week-by-week from 2.5mg to 15mg. Includes what to expect at each dose level, side effects by tier, printable download, and a free dosing calculator.

Who qualifies for GLP-1 therapy, how to get started, what to inject and when, and what to expect each week, with clinical trial data and pharmacokinetic context.

Complete Mounjaro (tirzepatide) dosage chart for type 2 diabetes. Covers the full 2.5 mg to 15 mg titration schedule, SURPASS-1 HbA1c reduction data, KwikPen injection guide, missed-dose rules, and dosing in special populations.

An educational, pharmacokinetics-grounded explainer of what a tirzepatide to retatrutide transition involves: washout timing, the 2mg restart, GI reset, and the investigational reality.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

A tirzepatide constipation guide covering the mechanism, brand-correct FDA label rates for Mounjaro and Zepbound, relief strategies, and when constipation becomes an emergency.

Everything you need to know about tirzepatide dosing: dual-agonist mechanism, clinical trial efficacy data, starting dose through maintenance, titration schedules, half-life pharmacokinetics, side effects, and dosing calculator.

Tirzepatide side effects guide: nausea, diarrhea, and other GI symptoms from clinical trial data, plus practical management tips.

Complete guide to tirzepatide weight loss: SURMOUNT trial results showed 20.9% average weight loss at 72 weeks on 15mg dose. How it works, what to expect, timeline, dosing, comparison with Ozempic/Wegovy, and managing side effects.

Tirzepatide is FDA-approved as Mounjaro and Zepbound, so you might assume alcohol has been studied. It has not. The prescribing information never addresses drinking at all. Here is what the label does say, and what that leaves you to reason about yourself.

There is no FDA-approved tirzepatide pill, and the reason is structural rather than a matter of timing. Tirzepatide is a peptide that stomach acid and digestive enzymes break down before it can be absorbed, which is why Mounjaro and Zepbound remain once-weekly injections. This guide covers why, what the approved oral GLP-1 pills actually are, and why orforglipron (Foundayo) is a different molecule rather than tirzepatide in tablet form.

What Mounjaro actually costs through LillyDirect, why the price does not step up by dose, and how the $25 savings card compares for insured patients.

A candidacy and treatment-management guide to Mounjaro (tirzepatide) for type 2 diabetes. Who qualifies, who is excluded, combining it with metformin or insulin, and how long people stay on it.

Complete guide to reconstituting compounded tirzepatide. Free calculator for BAC water volumes and insulin units, concentration charts for 5mg to 60mg vials, and expert storage tips.

Tirzepatide is FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Compounded tirzepatide is a different story. Here is the full approval timeline, brand-by-brand indications, eligibility, and the compounded vs brand distinction.

Mounjaro (tirzepatide) treats type 2 diabetes by activating two incretin receptors at once. Here is the organ-level physiology, the SURPASS-1 evidence behind its 2022 FDA approval, and how it compares to Ozempic in head-to-head trials.

Tirzepatide has two FDA-approved brand names, both from Eli Lilly: Mounjaro for type 2 diabetes (May 2022, NDA 215866) and Zepbound for chronic weight management (November 2023, NDA 217806). Same molecule, two indications, two boxes.

Mounjaro (tirzepatide) is Eli Lilly's once-weekly injectable for type 2 diabetes, FDA-approved May 2022. The first dual GIP/GLP-1 receptor agonist, with a 2.5 to 15 mg dose ladder and SURPASS trial backing.

Tirzepatide-associated hair shedding is real but almost always temporary telogen effluvium triggered by rapid weight loss. This guide covers mechanism, risk factors, prevention, and the 6-12 month recovery timeline.

Compounded tirzepatide costs a fraction of Mounjaro or Zepbound — see our full <a href="/resources/tirzepatide-cost" style="color: #2563eb;">tirzepatide cost guide</a> but sits at the center of an ongoing legal battle between Eli Lilly, compounding pharmacies, and the FDA. This guide covers the regulatory landscape after the October 2024 shortage removal, how to source safely, dosing considerations, reconstitution, storage, and what the court rulings mean for availability.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) on both HbA1c reduction and weight loss in the SURPASS-2 trial. Ozempic holds the cardiovascular edge. Full comparison inside.

Free tirzepatide dosing calculator plus complete guide. Visualize Mounjaro/Zepbound drug levels, plan titration schedules, understand half-life pharmacokinetics, and manage side effects.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

Tirzepatide activates two hormone receptors — GLP-1 and GIP — producing greater fat loss than GLP-1-only drugs. Here's what each receptor does, why the mechanism isn't fully understood, and what the clinical trials show.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.

While tirzepatide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.